ALGS: Aligos Therapeutics Inc

ALGS News

• 15:13 RCKT Stock Rises as FDA Lifts Clinical Hold on Danon Disease Study
• 12:37 Aligos Therapeutics appoints Ramón Polo as head of global regulatory
• 13:55 Wall Street Analysts Predict a 983.24% Upside in Aligos Therapeutics (ALGS): Here's What You Should Know
• 11:29 Aligos Therapeutics stock gets Buy rating from H.C. Wainwright on HBV drug potential
• 15:11 Allogene's Q2 Loss Narrower Than Expected, Pipeline in Focus
• 12:37 Aligos begins dosing in phase 2 HBV drug study
• 22:00 Aligos Therapeutics, Inc. (ALGS) Reports Q2 Loss, Misses Revenue Estimates
• 12:20 Aligos Therapeutics Appoints Kieron Wesson as Vice President, Head of Chemistry Manufacturing Controls (CMC)
• 01:14 Tracking Baker Brothers Portfolio – Q1 2025 Update
• 12:16 Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 13:44 Aligos Therapeutics to Present at the Jefferies Global Healthcare Conference
• 12:16 Aligos Therapeutics Appoints Laura Kavanaugh as Vice President, Head of Legal
• 12:16 Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 03:56 Tracking Baker Brothers Portfolio - Q4 2024 Update
• 16:59 Nasdaq, S&P 500 Hit 6-Month Lows As Recession Fears Grow: What's Driving Markets Monday? - SPDR S&P 500 (ARCA:SPY)